NASDAQ
Gene Biotherapeutics, Inc. (CRXM) has a fcf yield of -124.01% as of Friday, May 29, 2026. This represents a 99.57% decrease compared to its 12-month average of -62.14%. Free cash flow yield measures free cash flow per share as a percentage of the stock price, indicating cash return potential.
No price data available for this timeframe.